Protocol Review &Monitoring System The Protocol Review &Monitoring System (PRMS) at Moffitt Cancer Center facilitates the function of two Scientific Review Committees (SRCs), each staffed with appropriate faculty and scientific representation. Each committee meets once a month, with staggered meetings so that there is an SRC meeting approximately every two weeks. The SRCs provide the review for scientific merit and prioritization and monitor scientific progress for all protocols at the Cancer Center. SRC approval is required prior to IRB submission and the IRB will not consider a research study from the Cancer Center that has not been approved by the Moffitt Cancer Center SRC. The SRCs have reviewed between 180 and 200 new protocols each year of the grant for scientific merit. Protocols that have been previously peer reviewed by recognized peer-review agencies are expedited through the SRC process, but are reviewed administratively by the Chair or his designee. The committees review all ongoing clinical research studies for scientific progress and have the authority to suspend and close studies that are not making scientific progress towards their objectives. The Cancer Center is in the process of implementing the Oncore? clinical trials management software that will aid the PRMS in the administrative tracking of all research studies (pending and ongoing), as well as facilitate the committee process by helping to coordinate the committee membership, agendas, decisions and correspondence.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-12
Application #
8055319
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-02-01
Budget End
2011-01-31
Support Year
12
Fiscal Year
2010
Total Cost
$143,335
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Kim, Youngchul; Pierce, Christine M; Robinson, Lary A (2018) Impact of viral presence in tumor on gene expression in non-small cell lung cancer. BMC Cancer 18:843
Persi, Erez; Duran-Frigola, Miquel; Damaghi, Mehdi et al. (2018) Systems analysis of intracellular pH vulnerabilities for cancer therapy. Nat Commun 9:2997
Rosenberger, Albert; Hung, Rayjean J; Christiani, David C et al. (2018) Genetic modifiers of radon-induced lung cancer risk: a genome-wide interaction study in former uranium miners. Int Arch Occup Environ Health 91:937-950
Chen, Yan; Zhu, Jin-Yi; Hong, Kwon Ho et al. (2018) Structural Basis of ALDH1A2 Inhibition by Irreversible and Reversible Small Molecule Inhibitors. ACS Chem Biol 13:582-590
Kahen, Elliot John; Brohl, Andrew; Yu, Diana et al. (2018) Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors. Oncotarget 9:22571-22585
Hoffman, Melissa A; Fang, Bin; Haura, Eric B et al. (2018) Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. J Proteome Res 17:63-75
Puri, Sonam; Hyland, Kelly A; Weiss, Kristine Crowe et al. (2018) Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors. Support Care Cancer 26:2911-2918
Gonzalez, Brian D; Small, Brent J; Cases, Mallory G et al. (2018) Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia. Cancer 124:499-506
Eroglu, Zeynep; Zaretsky, Jesse M; Hu-Lieskovan, Siwen et al. (2018) High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553:347-350
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430

Showing the most recent 10 out of 1254 publications